Peregrine Pharmaceuticals reported $-1156000 in Net Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Agenus AGEN:US USD -54222000 7.79M
Amgen AMGN:US USD 2.14B 826M
AstraZeneca AZN:LN USD 1.64B 1.28B
Biocryst Pharmaceuticals BCRX:US USD -42520000 16.34M
Bristol Myers Squibb BMY:US USD 1.61B 185M
Eli Lilly And LLY:US USD 1.45B 499.2M
GlaxoSmithKline GSK:LN GBP 10.32B 9.48B
Immunogen IMGN:US USD -77755000 15.73M
Intrexon XON:US USD 87.38M 105.01M
Karyopharm Therapeutics KPTI:US USD -36324000 12.74M
Macrogenics MGNX:US USD -24813000 16.49M
Mannkind MNKD:US USD -14432000 14.59M
Merk MRK:US USD 3.25B 696M
Minerva Neurosciences NERV:US USD -6901000 1.82M
Newlink Genetics NLNK:US USD -7251000 593K
Novartis NOVN:VX USD 1.57B 121M
Peregrine Pharmaceuticals PPHM:US USD -1156000 2.72M
Repligen RGEN:US USD 40.4M 9.46M
Roche Holding ROG:VX 8.53B 2.4B
Xencor XNCR:US USD -32759000 1.22M